唑来膦酸治疗3年与6年后药物假期的成本效果比较
该研究针对美国绝经后骨质疏松且股骨颈骨密度T值在-2.5至-3.5之间的女性,用微观模拟模型比较唑来膦酸3年治疗/3年假期与6年治疗/3年假期的终生成本效果。结果显示3/3方案在10万美元/QALY支付意愿下始终更具成本效果,终生直接医疗成本平均低约2000美元。
要点
- 对于股骨颈T值-2.5至-3.5的绝经后女性,唑来膦酸3年治疗+3年假期比6年治疗+3年假期更具成本效果。
- 3/3与6/3方案终生QALY接近,但3/3方案终生直接医疗成本平均低约2000美元。
- 概率敏感性分析中,3/3方案在超过70%的迭代中被优选(支付意愿10万美元/QALY)。
核心结论
- 对于美国绝经后骨质疏松且股骨颈BMD T值-2.5至-3.5的女性,先3年唑来膦酸治疗再3年假期、之后重启治疗周期,终生成本效果可能优于先6年治疗再3年假期。
研究设计与样本
- 研究采用个体水平状态转换微观模拟成本效果模型,比较唑来膦酸3/3、6/3和不治疗三种策略的终生成本效果。
主要发现
- 基础病例分析及所有关键参数敏感性分析(治疗起始年龄50、60、70、80岁)均显示3/3策略始终最具成本效果(支付意愿10万美元/QALY)。
- 3/3与6/3策略终生QALY相对接近,但3/3策略终生直接医疗成本平均低约2000美元。
- 概率敏感性分析中,在10万美元/QALY阈值下,所有评估的治疗起始年龄中3/3策略在超过70%的迭代中被优选。
关键数值与推荐
- 支付意愿阈值设为10万美元/QALY。
- 目标人群股骨颈BMD T值范围为-2.5至-3.5。
- 唑来膦酸3/3方案定义为3年治疗后继以3年药物假期,6/3方案定义为6年治疗后继以3年假期。
临床怎么用
- 对符合股骨颈T值-2.5至-3.5的绝经后骨质疏松女性,可优先考虑唑来膦酸治疗3年后给予3年药物假期,而非持续治疗6年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We evaluated the cost-effectiveness of recurrent periods of 3 versus 6 years of zoledronic acid treatment prior to 3-year bisphosphonate holidays for US postmenopausal women with osteoporosis and femoral neck BMD T-scores between - 2.5 and - 3.5. We found that cycles of 3 years of treatment followed by holidays is likely to be the more cost-effective option. INTRODUCTION: We compared the effectiveness and cost-effectiveness of cycles of 3 years versus 6 years of zoledronic acid treatment prior to 3-year bisphosphonate holidays for US postmenopausal women with osteoporosis. METHODS: We developed an individual-level state-transition microsimulation cost-effectiveness model to compare treatment strategies over the lifetime of recurrent periods of 3 years of zoledronic acid followed by 3-year holidays (zoledronic acid 3/3), recurrent periods of 6 years of zoledronic acid followed by 3-year holidays (zoledronic acid 6/3), and no zoledronic acid treatment for women with osteoporosis and femoral neck BMD T-scores between - 2.5 and - 3.5. RESULTS: Base-case analysis and all key parameter sensitivity analysis findings for every treatment initiation age evaluated (50, 60, 70, and 80) revealed that zoledronic acid 3/3 was consistently the most cost-effective strategy, assuming a willingness-to-pay of $100,000 per quality-adjusted life-year (QALY). In general, the zoledronic acid 3/3 and 6/3 strategies were relatively close in effectiveness (QALYs) over the lifetime; however, lifetime direct health care costs were on average approximately $2000 lower for the 3/3 strategy. Probabilistic sensitivity analysis results revealed that the zoledronic acid 3/3 strategy was favored in greater than 70% of the iterations for a willingness-to-pay threshold of $100,000/QALY for all treatment initiation ages evaluated. CONCLUSIONS: After 3 years of zoledronic acid treatment for postmenopausal women with osteoporosis and femoral neck BMD T-scores between - 2.5 and - 3.5, taking 3-year holidays before restarting another treatment cycle is likely to be more cost-effective over the lifetime than cycles of 6 years of treatment prior to 3-year holidays.
引用
- Nayak S, Greenspan SL. Cost-effectiveness of 3 versus 6 years of zoledronic acid treatment before bisphosphonate holiday for women with osteoporosis. Osteoporos Int. 2021. PMID: 34515818. doi:10.1007/s00198-021-06010-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。